Zero To Hero
A bio tech company was looking to expand its operations internationally. It also had managed to acquire U.S. Food and Drug Administration approval for a promising antiviral. However, before it could foray into the international market, it needed a setup that would allow it to guarantee quick delivery of large quantities of the drug. At the time, this company had fewer than 100 employees and no existing manufacturing or supply chain capabilities. A major challenge for the company was to secure global production and supply chain capacity without a clear idea of the total market size or even which markets would place orders. This uncertainty made it difficult to decide on the investment needed and also created problems in the process of vendor selection and negotiation. The model needed to work for both near-term orders and the full-scale commercial launch. For a successful resolution to its troubles, the company sought help from Deloitte, a leading outsourced business consulting company. Deloitte worked closely with the company and helped it draw up a plan that also included production schedules and vendor solicitation. The plan was a comprehensive one, having taken everything into consideration; from technical specifications to due diligence on technical capabilities for all dimensions - raw materials, active pharmaceutical ingredient (API), synthesis, formulation, fill and finish and packaging. A variety of distribution scenarios was also covered so as to better prepare the company to deal with all kinds of supply situations.